The Sixteenth Annual Pharmaceutical Regulatory and Compliance Congress will take place October 21 – 23, 2015 at the Mandarin Oriental in Washington, D.C.
The conference is scheduled to take place over three days; however, the last day is a closed session for an industry-only compliance best practices think tank.
On Wednesday, October 21, there are four different pre-conference tracks in the morning before the conference officially begins at 1:00 pm. The pre-conference tracks cover a wide variety of topic areas, including: basic principles of regulatory concepts; innovations in risk assessment, auditing and monitoring; taking data to the next level in domestic and global transparency; and global compliance issues. Once the conference officially gets under way, the first keynote will be an update provided by Mary E. Riordan, Esq. of the Office of Inspector General of the Health and Human Services. Following Ms. Riordan’s update from the HHS OIG, the next keynote will be an update on the Food and Drug Administration’s Office of Prescription Drug Promotion, given by Thomas W. Abrams. The first day ends with an expert panel discussing an FCPA Anticorruption case, with input from the Department of Justice, the Securities and Exchange Commission, and compliance officers.
On Thursday, October 22, the morning starts out with updates from the DOJ and CMS. The middle of the day includes several different break-out sessions, covering multiple topics, such as: the recommended pre- and post-deal due diligence for companies acquired by other companies; how to evaluate compliance program effectiveness; how to coordinate risk management across the control functions; and innovation in training and communications. The day ends with a panel on millennials and the future of ethics and compliance programs and a keynote speech by Robert Barrington, PhD, on Transparency International’s New Pharma Industry Initiative.
As previously mentioned, the final day, Friday, October 23, is a closed session where attendance is limited to company compliance professionals and in-house counsel to facilitate a more focused exchange of views regarding issue priority and effective compliance practices.
If you’re interested in attending the Sixteenth Annual Pharmaceutical Regulatory and Compliance Congress, you can register here.